STUDresearch · Peptide
Sermorelin
Also known as
Sermorelin acetate · GHRH 1-29 · GHRH (1-29) · GHRH (1-29) NH2 · GRF 1-29 · GRF 1–29 · GRF 1-29 NH2 · Geref (historical brand) · Geref Diagnostic (historical brand) · Sermorelin acetate injection
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Lots of talk
Systemic
SubQ; historical IV diagnostic use
Growth hormone axis
Systemic — short-acting GHRH(1-29) fragment that pulses pituitary GH release; downstream IGF-1 and whole-body recovery/sleep/body-comp effects.
What people say
Sermorelin is the 29-amino-acid GHRH fragment discussed for sleep and recovery. Historical Geref also contained sermorelin acetate; its products and indications differ from current compounded adult-wellness use.It is distinct from CJC-1295, Mod GRF, tesamorelin and ipamorelin.
Doses people talk about
Reports and marketing charts are distinct from historical Geref indications; neither establishes an adult-wellness dose ladder.
How it may feel
Reports range from better sleep after about a week to worse or fragmented sleep, early waking, or no clear benefit after more than a month.
Nightly community / clinic discussion100–300 mcg per night
The existing notes most often name 200–300 mcg. One inspected nonresponse account describes 200 mcg on a 5-on/2-off schedule.
Higher chart discussion400–500 mcg per night
Preserved from the existing guides, not a proven ceiling or a dose-related sleep-disruption threshold.
Half-life & effect duration
- Half-life in the body
- Historical Geref · IVAbout 6–7 minutes
- Community / clinic estimatesAbout 10–12 minutes; broader reports give 10–20 minutes
- Older constant-infusion estimateAbout 4.3 minutes
- Felt duration people report
- Immediate community reportsFlushing or warmth fading after about 5–15 minutes
- Positive sleep accountBetter sleep after about 1 week
- Other accountsWorse sleep during 12 days, or no clear benefit after more than 30 days
- Break accountImprovement during a 2-day break
Cycles people discuss
Forum and clinic accounts describe 8–12 weeks, three-to-six-month blocks, 5-on/2-off schedules and open-ended use.
Timing
Bedtime is common; some people move use earlier or to morning when nighttime sleep worsens.
Stacks
+ Ipamorelin (top dual): GHRH fragment + selective GHRP; most common modern clinic/forum pair for sleep and recovery. Typical talk: both at bedtime, same syringe or premix; ~200–300 mcg class each or labeled blend draws.
Access talk
Compounding argument: 503A pharmacies still fill patient-specific Rx because it was a component of an approved (now discontinued) drug — that statutory hook is what clinics mean by “legal GHRH.” Trackers that only read the May 2026 503A category PDF often report sermorelin as not listed there. Both sentences circulate.
Labs people mention
IGF-1: Baseline and ~6–8 / ~12-week checks recur in clinic-style discussion. Comparisons with DAC or rGH remain in the notes, but a short parent-peptide half-life does not establish a morning IGF-1 trough or predict how far that downstream marker will move.
Watch for
Injection site: Pain, redness, swelling, itching — most frequent complaint and historical label “more common” local reaction.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
About 6–7 minutes after intravenous administration in historical Geref information.
The separate 2–3-hour figure describes the GH response, not sermorelin remaining in the body or a felt effect.
Existing 10–12-minute community/clinic figures remain in the original notes; this verified historical IV document does not adjudicate every route, assay or secondary estimate.
- Historical Geref 50 product information (opens in a new tab)Page 2, section 5.2; text revision May 2004, printed July 2006. Intravenous elimination and separate GH-response duration.Historical diagnostic intravenous formulation. It does not verify present-day subcutaneous, sublingual or mixed products.
Felt duration people report
One person noticed better sleep after a week; others described worse sleep during 12 days or no clear benefit after more than 30 days at 200 mcg on a 5-on/2-off schedule.
These are changes during a course, not a dependable number of hours per dose; a two-day-break improvement was also reported.
Experiences conflict and are not prevalence estimates. Training and other circumstances can affect perceived recovery; the observations do not establish a safe cycle or preferred hour.
- Sermorelin results — contrasting sleep accounts (opens in a new tab)dstcyr17 original post: sleep after one week and later training changes; later confirms use by itself. Old_Time_121 reply: worse sleep over 12 days and better during a two-day break.Selected uncontrolled reports; identity, causality, lab results and product quality are unverified. Later combinations are not evidence for the initial solo course.
- Sermorelin: more-than-month nonresponse account (opens in a new tab)Sad-Buyer9012 opening 200 mcg 5-on/2-off and more-than 30-day nonresponse. Independent actual content inspection September 6.Self-reported amount, schedule and product; no controlled comparison or efficacy conclusion.
- Sermorelin: sleep and clock-time discussion (opens in a new tab)Opening sleep issue and earlier/morning timing replies. Independent actual content inspection September 6; wearable estimates and identity unverified.Sleep and wearable estimates are unverified. The reviewed passages do not establish a 400–600 mcg sleep-disruption threshold.
What people say
- Sleep: Deepest/most restorative sleep and easier fall-asleep are the earliest and most repeated solo-sermorelin community signals with bedtime dosing. forum
- Recovery: Easier between-session bounce-back and less next-day soreness over multi-week runs — usually with training still in the picture. forum
- Body composition: Gradual lean-mass / fat-shift talk over months; diet, training, and stacks (especially + Ipamorelin) heavily confound attribution. forum
- IGF-1 labs: Clinics track serum IGF-1 (baseline → ~6–8 weeks → ~12 weeks) as a GH-axis surrogate more than a subjective “feel.” forum
- Vs exogenous rhGH: Framed as preserving pituitary feedback and producing pulse-like GH rather than flat supraphysiologic exposure — lower “GH sides” lore vs high-dose somatropin, though not risk-free. forum
- Skin / wellness: Soft skin-quality, energy, and “feel younger” anecdotes; high placebo and lifestyle confound risk. anecdote
- Stack caveat: Many “sermorelin wins” on forums are actually Sermorelin + Ipamorelin (or other GHRP) dual-pathway protocols; solo attribution is unreliable. forum
- 2026 sleep-first still: X posts still time the first 1–2 weeks to sleep depth on a night empty-stomach pin; body-comp stays slow. forum
- Older-adult GHRH analog trial signal: Khorram et al. 1997 — nightly [Nle27]GHRH-(1-29)-NH2 at 10 µg/kg for 16 weeks in adults 55–71 raised nocturnal GH and IGF-1; men showed lean-mass, insulin-sensitivity, well-being, and libido gains more than women; skin thickness rose both sexes; sleep quality questionnaires were not improved in that design. trial
- Pediatric growth (historical): Geref-era data supported growth-rate improvement in some GH-deficient children at ~30 µg/kg bedtime subQ — different population and goal than adult wellness charts. trial
- Nitrogen / anabolic talk: Older GHRH-analog work showed trends toward positive nitrogen balance; not a modern physique trial. trial
Doses people talk about
- Modal adult band: ~200–300 mcg once nightly subQ is the most repeated “standard” across pharmacy blogs and protocol pages. forum
- Start band: ~100–200 mcg nightly common for first exposure or insulin-resistant/overweight patients where early water retention is a concern; some titration charts start ~100 mcg for 1–2 weeks. forum
- Maintenance talk: ~200–300 mcg nightly often called maintenance after titration. forum
- Upper band: ~400–500 mcg nightly appears as a higher ceiling in some guides when IGF-1/response at 300 mcg is “not enough”; higher is not automatically better because somatostatin caps the GH pulse. forum
- Wide published clinic range: ~100–500 mcg daily subQ at bedtime covers nearly all adult wellness charts surveyed. forum
- Timing — bedtime default: 30–60 minutes before sleep is the dominant instruction; some pharmacy charts say 60–90 minutes after the last meal. forum
- Empty stomach: Wait ~1–2 hours after food (especially carbs); insulin/FFA near meals are thought to blunt the GH response. forum
- Frequency default: Once-daily evening; multi-pulse (2–3×/day) is less common for solo sermorelin than for GHRP or CJC/Ipam stacks, but some blend clinics split doses. forum
- 5 nights on / 2 off: Very common clinic schedule (often weekdays on, weekend off) — rationale is cost, compliance, and folklore about preserving pituitary responsiveness / working with somatostatin rather than constant nightly stimulation. forum
- 7 nights continuous: Also common in “steady-state” research-context protocols; superiority of 5/2 vs 7 is not proven head-to-head. forum
- With older GHRPs: Bodybuilding-era charts pair Sermorelin with GHRP-2 or GHRP-6 for bigger pulses; hunger (GHRP-6) and cortisol/prolactin lore (GHRP-2) drive preference toward Ipamorelin in newer write-ups. forum
- Saturation lore: Community claim that past a point more mcg does not linearly raise GH because somatostatin shuts the pulse down — used to argue against mega-dosing solo Sermorelin. forum
- 2025–26 extra camps: 200–300 mcg nightly 7 days; 5-on/2-off; 100–200 start; 400–500 only if 300 “did nothing” — saturation/somatostatin lore still argues against mega-dosing solo. forum
- Split vs bedtime: Solo sermorelin stays a bedtime peptide in most 2026 charts. Dual with IPA may split, but night is still the kept dose. forum
- Troche vs pin math: Needle-free 300/200 or 600/300 mcg sermorelin/IPA troches are marketed; forums do not treat those micrograms as 1:1 with subq. forum
- Age-banded clinic charts (marketing, not RCTs): Examples include ~0.15–0.25 mg (150–250 mcg) ages 30–45; ~0.2–0.3 mg ages 46–60; ~0.1–0.2 mg ages 61+ — treat as clinic heuristics, not validated schedules. forum
- Multi-step clinic charts: Marketing examples describe weeks 1–2 near 100 mcg, weeks 3–4 near 200 mcg, weeks 5–8 near 300 mcg, and weeks 9+ toward 400–500 mcg only if the chart considers it needed, with lab monitoring. These provider-specific ladders are recorded as marketing practice, not validated or recommended adult schedules. forum
- FDA-era adult-context numbers cited: Historical prescribing discussion around ~0.2–0.3 mg/day (200–300 mcg) is frequently recycled into modern adult charts — adult anti-aging was never a large modern RCT endpoint. forum
- With Ipamorelin (dual stack): Discussed templates include Sermorelin ~250–300 mcg + Ipamorelin ~200–300 mcg same night (sometimes slightly lower Sermorelin than solo because dual signal amplifies); equal ~100/100 or ~200/200 also appear; clinic blends may quote a single total-peptide draw (e.g. ~300 mcg of blend at 0.2 mL of a labeled concentration). forum
- Premixed / troche ratios (compounder-dependent): Examples marketed: Sermorelin/Ipamorelin 300/200 mcg troche, 600/300 mcg troche, and multi-mg injectable blends (e.g. 15/15 mg vial talk) — always read the label; ratios are not standardized. forum
- Older-adult research dose example: Khorram 1997 used ~10 µg/kg nightly of a related GHRH 1-29 analog for 16 weeks — weight-based research context, not the flat 200–300 mcg clinic meme. trial
- Framing: Ranges below are clinic-marketing, compounding charts, and community discussion — not prescriptions, not medical advice, not safety-validated adult wellness protocols. forum
- Pediatric historical (Geref): ~30 µg/kg body weight subQ once daily at bedtime for childhood GHD growth failure — not an adult anti-aging calculator. trial
How it may feel
- Minutes after shot: Brief facial flush/warmth is classic within minutes and often fades in ~5–15 minutes; some only notice the needle. forum
- Nights 1–7: Site awareness common; sleep depth or vivid dreams may shift within the first week if bedtime + empty-stomach timing is solid. forum
- Weeks 1–2: Flushing/headache often settle; check empty-stomach window and whether dosing is too close to a carb-heavy dinner. forum
- Weeks 2–4: Sleep/recovery logs that “stick” often land here; body-comp change is still rare without lifestyle drivers. forum
- Weeks 4–8: Common first IGF-1 / thyroid recheck window in clinic-style talk; mild water retention or hand tightness more noticeable if dose or stack is aggressive. forum
- Months 2–3: Body-comp/energy/skin stories become more common in logs; still confounded by diet and training. forum
- Months 3–6: Full-benefit window many clinic pages claim; labs and cost usually drive continue / adjust / switch decisions. forum
- After stop: Sleep/recovery edge may fade over days–weeks; some notice little drop if lifestyle already carried results. anecdote
- 2025–26 nights: Flush minutes after the shot, then sleep change if bedtime + fasted is real. Fed pins get the same “why am I awake” posts as other GHRH shots. forum
- Vs CJC/IPA feel: Some switchers say sermorelin is “quieter” (shorter pulse); others say they needed IPA with it before anything showed. forum
Around the dose
- Clock: Bedtime, empty stomach — classic secretagogue slot. forum
- Sleep: The pairing. Sermorelin without sleep is just a pin in those threads. forum
- Training: Next-day training stays. Not a gym-bag peptide. forum
- Empty-stomach night pin: 30–90 min before sleep, ~1–2 hours after food — still the 2026 clinic-forum hybrid. forum
- Split vs bedtime: Bedtime is the default. Morning exists for people who cannot fast after dinner. forum
- After: Sleep. A sermorelin pin then screens-on is the usual “why no pulse” post. forum
- Not DAC: Minutes-scale half-life. Do not weekly-dose it like CJC with DAC. forum
Cycles people discuss
- Clinic style: Multi-month continuous or 5/2 nightly use with labs/symptoms reviewed roughly every 6–12 weeks. forum
- Common block length: ~3–6 months at a target dose is the most repeated “full effect” window in wellness marketing. forum
- Forum blocks: Often 8–12+ weeks then reassess sleep, recovery, IGF-1, cost, and whether to continue or switch agents. forum
- 3 months on / 1–2 weeks off: Some clinics describe quarterly blocks with short breaks before another ~3 months. forum
- On/off patterns: 5-on/2-off and weekdays-only are popular; evidence of superiority over daily is anecdotal. forum
- Open-ended longevity use: Multi-year adult compounded use is discussed under ongoing supervision talk; there is no robust long-term safety database for unmonitored wellness use. forum
- Switching: Common pivot to CJC-1295 (no DAC) + Ipamorelin or other secretagogue blends if cost, response, or convenience disappoints; tesamorelin enters when visceral-fat / HIV-lipodystrophy-adjacent talk dominates. forum
- Missed dose: Skip and resume next night — do not double or redose mid-morning in standard community guidance. forum
- 2026 clinic cadence: IGF-1 around 6–8 and ~12 weeks still shows up on wellness pages; 3–6 month blocks with 5/2 nights. forum
Timing
- Historical IV parent half-life: Geref information reports 6–7 minutes. Existing community/clinic ~10–12-minute, broader ~10–20-minute and older constant-infusion ~4.3-minute reports remain different route/assay contexts, not verified equivalents for current compounded SC products. trialforum
- Nightly rather than weekly discussion: Community explanations describe a ~1–2-hour GH pulse and alignment with the natural nocturnal pulse, unlike a DAC-style depot. That rationale does not establish SC parent clearance, felt duration or bedtime superiority. Historical IV Geref separately describes a 2–3-hour GH response. forumtrial
- Downstream cascade: Peptide → acute GH pulse → IGF-1 / IGFBP-3 rises over days–weeks; subjective recovery and body-comp stories lag the pulse by weeks–months. forum
- Empty stomach rationale: Near-meal glucose/insulin and free fatty acids are thought to blunt GH response to GHRH. forum
- Vs CJC-1295 with DAC: Sermorelin = short sharp pulse, daily; CJC+DAC = multi-day half-life and less “physiologic pulse” lore, fewer injections but different side/feedback talk. forum
- Vs CJC no-DAC / Mod GRF 1-29: Related short GHRH analogs with modified sequences and somewhat longer practical windows in bro talk; often preferred partners for multi-pulse day stacks. forum
- Missed / late dose: Community default is skip if you wake up late rather than inject into a fed morning and call it equivalent. forum
- Clearance: Rapidly cleared; adult clearance values in historical labeling discussion on the order of ~2.4–2.8 L/min. trial
- Vs tesamorelin: Longer/stabilized GHRH analog with distinct clinical history (e.g. visceral adipose indication lore); not interchangeable dose charts. trial
- Thyroid interaction: Untreated hypothyroidism can blunt GH response to GHRH; historical Geref-era monitoring included thyroid checks — some trial participants developed hypothyroid signals on therapy. trial
More on what it is
- Why people use it: Longevity-clinic and peptide-forum staple for sleep, recovery, and gradual body-comp talk without injecting recombinant GH. forum
- How it works (talk): Binds pituitary GHRH receptors → brief endogenous GH pulse → IGF-1 rise over weeks; somatostatin negative feedback still caps runaway GH, which is the common “more physiologic than fixed high-dose rhGH” pitch. forum
- Compounding context: Adult wellness use is off-label compounded; community write-ups note 503A compounding status discussions that differ from Category-2 peptides — verify current FDA/state rules, not static lore. forum
- 2026 access talk: Geref is still discontinued (commercial, not a safety withdrawal). Clinic pages call compounded sermorelin the “legal GHRH” because it was once an approved finished drug; independent trackers reading FDA’s May 14, 2026 503A category PDF often say sermorelin is not listed there. Compounding-with-Rx still happens — that is access talk, not a bulks-list listing. forumtrial
- Vs CJC/IPA in 2026: When shops won’t fill CJC or ipamorelin, sermorelin ± IPA is the pivot many telehealth protocols name. forum
- What it is: Synthetic 29-amino-acid N-terminal fragment of endogenous GHRH (44 aa); also called GRF 1–29 / GHRH (1-29) NH2; marketed historically as Geref / Geref Diagnostic. trial
- Half-life distinction: Historical IV Geref information gives a 6–7-minute parent half-life and a separate GH response peaking around 30 minutes and lasting 2–3 hours. Older ~10–12, ~10–20 and ~4–5-minute estimates concern other or incompletely verified contexts, not established current compounded-SC clearance. trial
- Regulatory history: FDA-approved as Geref for pediatric idiopathic GHD (NDA ~1997 treatment; diagnostic amp earlier ~1990); manufacturer discontinued branded product ~2008 for commercial reasons — FDA later determined withdrawal was not for safety/effectiveness. trial
- Not the same as: Not rhGH/somatropin, not a GHRP alone, not CJC-1295 (with or without DAC), not tesamorelin (stabilized GHRH analog with different indication lore), not Mod GRF 1-29 / CJC no-DAC (related short GHRH analogs with different half-life talk). trial
- Evidence honesty: Pediatric GHD and diagnostic use have historical label/trial footing; adult anti-aging/body-comp claims rest mostly on small older GHRH-analog studies (e.g. nightly GHRH 1-29 analogs in older adults), clinic protocols, and forums — not large modern RCTs for wellness endpoints. trial
Stacks
- + Ipamorelin (top dual): GHRH fragment + selective GHRP; most common modern clinic/forum pair for sleep and recovery. Typical talk: both at bedtime, same syringe or premix; ~200–300 mcg class each or labeled blend draws. forum
- + GHRP-2: Older bodybuilding dual-secretagogue charts; stronger pulse lore, more side-effect baggage than Ipamorelin. forum
- + GHRP-6: Big GH pulse + strong hunger; used less now when appetite control matters. forum
- + Hexarelin: Aggressive GHRP stack talk; desensitization/cortisol lore keeps it niche vs Ipamorelin. forum
- Lifestyle axis: Often layered with sleep hygiene, protein, resistance training, and sometimes MK-677 — highly confounded attribution. forum
- Repair season: Sometimes + BPC-157 and/or TB-500 during injury or high-volume training blocks (“recovery stack” marketing). forum
- Vs / not usually with high-dose rhGH: Conceptually compared to low-dose somatropin more than co-administered at bodybuilding GH doses; combining secretagogues with exogenous GH is a separate risk conversation. forum
- TRT adjacency: Men’s clinics sometimes run Sermorelin alongside testosterone replacement — confounds wellness outcomes. forum
- Same-syringe practice: Drawing Sermorelin + Ipamorelin together for one subQ shot is common; a minority prefers separate injections or pharmacy-premixed vials only. forum
Access talk
- Compounding argument: 503A pharmacies still fill patient-specific Rx because it was a component of an approved (now discontinued) drug — that statutory hook is what clinics mean by “legal GHRH.” Trackers that only read the May 2026 503A *category* PDF often report sermorelin as not listed there. Both sentences circulate. forumtrial
- Vs CJC/IPA access: 2025–26 telehealth menus lean sermorelin when they will not ship CJC or ipamorelin after the 2024 PCAC no-votes. forum
- Gray RUO sermorelin still exists beside pharmacy lots — same name, different identity controls. forum
- Formerly approved, not currently marketed: Geref / Geref Diagnostic were FDA-approved; manufacturer discontinued ~2008 for commercial reasons; FDA later recorded the withdrawal as not for safety/effectiveness. No branded sermorelin is on the U.S. market in 2026 clinic writeups. trial
- Not in the July 2026 PCAC seven and not in the April 2026 Category-2 removal twelve. Those headlines were other peptides. trial
Labs people mention
- IGF-1: Baseline and ~6–8 / ~12-week checks recur in clinic-style discussion. Comparisons with DAC or rGH remain in the notes, but a short parent-peptide half-life does not establish a morning IGF-1 trough or predict how far that downstream marker will move. forum
- Glucose: milder solo, watched harder in stacks or prediabetes. forum
- If IGF-1 is flat: timing/food, dose still at 100 mcg, missing IPA partner, or compounded fill — 2026 threads check those before 500 mcg. forum
- Thyroid: Historical Geref-era monitoring included thyroid because hypothyroidism can blunt GHRH response — still in careful protocol talk. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
- Clinic cartridge vs RUO vial: Unit marks on a compounded pen are not the same as a 5 mg research vial plus mystery water. Blend 15/15 mg sermorelin/IPA talk exists — read the label; this card still has no mix SOP. forum
Watch for
- Water retention / edema: Mild bloating or hand/foot puffiness early or when stacked with other GH-axis agents; more “GH side” than unique to sermorelin. forum
- Joint aches / carpal-tunnel-like tingling: Discussed at higher exposure or stronger stacks as IGF-1/GH-related fluid effects — more common in rhGH lore but appears in secretagogue side lists. forum
- Appetite: Hunger more often blamed on GHRP partners (especially GHRP-6) than solo sermorelin. forum
- Compounding quality: Research-chem and compounded product ≠ historical branded Geref QC; underfilled or impure vials are a community failure mode. forum
- Route caveats: Nasal/troche convenience can trade off against uncertain bioavailability; needle-free is not automatically “equal dose, equal effect.” forum
- Not risk-free: Pediatric history + business-only discontinuation of Geref ≠ proof that unmonitored adult anti-aging use is risk-free. forum
- Water / carpal / glucose: Milder in solo sermorelin talk than high-IU HGH, but stacks (IPA, MK-677) bring the GH-axis triad back. forum
- Compounded ≠ Geref: 2026 fills are pharmacy lots, not the discontinued brand’s QC. forum
- Injection site: Pain, redness, swelling, itching — most frequent complaint and historical label “more common” local reaction. trial
- Flushing: Transient facial warmth/flush within minutes of injection; often resolves in minutes. trial
- Headache: Minority systemic report, especially early weeks. trial
- Dizziness / sleepiness / restlessness: Listed in historical and clinic side-effect summaries; usually framed as transient. trial
- Dysphagia / strange taste / chest tightness: Less common label-era systemic reports; stop-and-seek-care language appears in consumer drug monographs for severe allergic patterns. trial
- Hypersensitivity: Rash, hives, difficulty breathing, facial/oral swelling — rare but serious pattern in safety write-ups. trial
- Glucose / insulin sensitivity: Theoretical metabolic concern when amplifying GH/IGF-1; diabetics/prediabetics are told to monitor in clinic materials; older GHRH-analog work also reported mixed insulin-sensitivity signals by sex. trial
- Transient hyperlipidemia: Reported as the main adverse lab note in Khorram 1997 GHRH-analog study, resolving by study end. trial
- Thyroid: Hypothyroidism can blunt response; some patients on therapy need thyroid labs because GH axis and thyroid interact — monitor talk is standard in careful protocols. trial
- Pregnancy / pediatric off-label: Adult wellness protocols should not be casually extrapolated; historical pediatric use was specialist-supervised GHD treatment. trial
- Mitogenic / long-term GH-axis caution: Elevating GH/IGF-1 has theoretical concerns (proliferation, occult malignancy risk framing) shared with the whole secretagogue class — not proven safe by long-term wellness RCTs. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.